May 3, 2024 09:52 AM EDT
R&D

AEON fails an­oth­er mi­graine tri­al, shares halve as com­pa­ny re­views op­tions

Kyle LaHucik

Senior Reporter

AEON Bio­phar­ma said its bot­u­linum tox­in treat­ment can­di­date failed a Phase 2 mi­graine study at the planned in­ter­im analy­sis. The com­pa­ny’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Vi­a­tris' In­dia-based man­u­fac­tur­ing site blocked from ship­ping 11 gener­ic drugs to US

A service from the Financial Times